04 July 2025
04 July 2025
More than half of the top 15 pharma companies are expected to face challenges in managing the patent cliff.
Key aims include shifting to a preventative service as opposed to a sick care service, with a focus on driving this with technology.
The acquisition will bring the Nasdaq-listed Theratechnologies back under private ownership.
The BV500 programme is based on BioVersys’ Ansamycin Chemistry platform.
Clinical trials have demonstrated that both biosimilars match the reference product's quality, safety and efficacy standards.
Ligand will receive a 13% royalty on global net sales of Zelsuvmi.
Joincare gains exclusive rights to research, develop and commercialise BRII-693 within the Greater China region.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
